Skip to content
Sign in
2026 World Champion

ZymoChem

Carbon-efficient microbial fermentation platform producing BAYSE, a bio-based superabsorbent designed to replace petroleum SAP in hygiene products.

San Francisco Bay Area, California, United States, North AmericaBiotech & life sciences, Synthetic biology – bio-based materials2026 Grand Finale champion ($1M from Pegasus)
Stage
Series ANo documented AI
Product
PilotPilots / LOIs
Funding raised
$25Mdisclosed
Founded
201313 years ago
Founders
2Harshal, Jon
Global score
5.8Grade CRank 17 of 151

Overview

ZymoChem uses microbial fermentation to produce high-performance materials without fossil energy. Its first product, BAYSE™, is a bio-based superabsorbent intended to replace petroleum-based SAPs in diapers and hygiene products.

Traction

Pilots / LOIs

BAYSE in testing (home-use test in 2026, key ingredient produced at commercial scale); no named commercial customer.

Market

Superabsorbent polymers (SAP)

Superabsorbent polymers are a large commodity ingredient in diapers, feminine care and incontinence products, almost entirely petroleum-based acrylic. Hygiene majors face extended producer responsibility, plastic-reduction pledges and consumer demand for bio-based claims, which creates pull for a drop-in bio-based SAP. Adoption requires performance parity, cost close to fossil SAP and multi-year qualification by a few global buyers. ZymoChem's platform can extend to other materials, as its lululemon and Toyota backing suggests.

Addressable market

2025
$10.2B
2030
$14.4B
+7.1% a year

Superabsorbent polymers (SAP): $10.2bn in 2025, +7.1%/year (Persistence Market Research), bio-based share still nascent.

Customers

Global hygiene manufacturers (diapers, femcare, adult incontinence) and SAP buyers; later, apparel and other materials users.

Who signs the cheque

Procurement and R&D/materials leads at hygiene majors; strategic partners.

Geographies

  • United States
  • Global hygiene supply chains

Drivers

  • Plastic reduction and EPR regulation
  • Corporate net-zero and bio-based content targets
  • Advances in strain engineering lowering fermentation cost

Headwinds

  • No named commercial customer yet
  • Industrial scale-up cost and price parity with fossil SAP
  • Long qualification cycles at a few concentrated buyers

The global SAP market is estimated at $10.2bn in 2025 (+7.1%/year, $16.5bn in 2032) according to Persistence Market Research ($9.8–12.1bn depending on the source), of which the bio-based share is still nascent.

Scalability 6/10. Ingredient that can be sold to major global hygiene manufacturers, but scaling up fermentation industrially is costly.

Market source: persistencemarketresearch.com

Technology

Category

Industrial biotechnology / synthetic biology materials

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

pilot

How it works

Engineered microorganisms convert sugar into chemical intermediates with high carbon yield, which are then polymerised into biodegradable materials. BAYSE is the first product, a bio-based superabsorbent.

Moat

Strong scientific moat: carbon-efficient strain engineering and polymer know-how from UC Berkeley/LBNL roots, DOE/LBNL funding and strategic investors; commercial moat depends on first offtake contracts.

Differentiation

Fermentation-derived, biodegradable SAP versus petroleum acrylic SAP and versus bio-SAP approaches with lower carbon yield.

Integration points

  • Hygiene product lines (drop-in SAP)
  • Compostable plastics components
  • Materials simulation and formulation tools
  • Apparel and consumer brands (via strategic investors)

Depends on

  • Sugar feedstock and contract fermentation capacity
  • Skin-safety and performance qualification by hygiene brands
  • Biodegradation and bio-based certifications

Use of AI

No use of AI mentioned

Product in detail

Platform for engineering high carbon-yield microorganisms (efficient conversion of sugar into chemical intermediates), with polymerization into biodegradable materials.

Business

Model
B2B ingredient sales or licensing to hygiene manufacturers (pricing not disclosed).
Revenue logic
Price per tonne benchmarked against fossil SAP; margin driven by carbon yield and fermentation scale.
Go-to-market
Partnerships with hygiene majors via home-use tests, supported by strategic investors and federal programmes.

Next milestones

  1. First named commercial supply contract for BAYSE
  2. Demonstrated cost path to parity at scale
  3. Second application (e.g. apparel with a strategic investor)

Key risks

  • Scale-up cost overruns
  • Customer adoption timelines
  • Price parity versus commodity SAP

Opportunities

4 found in the network

Concrete moves for ZymoChem inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Co-development 2
  • Investors 1
  • Peers 1

Co-development2

An integration or joint product

Fully compostable absorbent product with a degradation additive

A diaper is only as compostable as its plastic components. EvoNatura supplies a heat-resistant microbial additive that lets compostable plastics fully degrade; combined with BAYSE, hygiene brands could be offered a bio-based core plus degradable films, a stronger proposition than either material alone.

25%confidence

Evidence from the records

  • “bio-based superabsorbent intended to replace petroleum-based SAPs in diapers and hygiene products”
  • “Thermostable "drop-in" microbial additive (up to 220 °C) compatible with existing production lines”
If it works
A joint material package for hygiene brands and a lighthouse application for EvoNatura.
First step
Organise a joint call to map which diaper components (backsheet, topsheet, packaging) EvoNatura could address.

Simulation-guided SAP formulation

SAP performance (absorbency under load, gel strength) depends on polymer network structure. Caldera Engine simulates macromolecular suspensions with AI to predict material properties, which could cut the number of polymerisation trials needed to reach performance parity.

20%confidence

Evidence from the records

  • “polymerization into biodegradable materials”
  • “Caldera Engine: physics simulation of macromolecular suspensions coupled with AI to predict material properties.”
If it works
Faster formulation cycles and a flagship materials customer for Monte Caldera.
First step
Request a Caldera Engine trial on a non-confidential hydrogel system.

Investors1

A fund whose thesis fits

Catalytic capital for plant scale-up

ZymoChem's next challenge is capital-intensive scale-up; Temasek Trust's catalytic vehicle invests in Climate & energy and HealthTech and joined Neocrete's 2026 round in the network.

20%confidence

Evidence from the records

  • “Climate & energy”
  • “Catalytic Capital for Climate and Health (Temasek Trust)”
  • “Costly industrial scale-up”
If it works
A catalytic co-investor that crowds in Asian capital for manufacturing scale-up.
First step
Ask Neocrete's CEO for an introduction to the Temasek Trust investment team.

Peers1

Founders solving the same problem elsewhere

Davis fermentation network and scale-up playbook

ZymoChem's CEO trained at UC Davis, where Yeast Bay Bio was founded in 2025. Sharing contract-fermentation contacts, scale-up lessons and DOE/grant experience is low cost and high value for a seed-stage fermentation company.

25%confidence

Evidence from the records

  • “PhD in chemistry (UC Davis)”
  • “founded in 2025 in Davis (California)”
If it works
Mentoring and shared supplier network that shortens Yeast Bay Bio's scale-up path.
First step
Invite Yeast Bay Bio's founders to a 1-hour session on contract fermentation partners.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Ranked by thesis affinity

  1. Invests in Biotech & life sciences · Writes Series A cheques

    Intro via Pleryon Therapeutics, backed by EFung Capital

    86High fit
  2. Invests in Biotech & life sciences · Active in United States

    Intro via Defined Bioscience, backed by U.S. National Institutes of Health (NIH)

    80High fit
  3. Invests in Biotech & life sciences · Writes Series A cheques

    Intro via PolyJoule, backed by Sands Capital Ventures

    79High fit
  4. Invests in Biotech & life sciences · Active in United States

    Intro via Monte Caldera Technologies Inc., backed by MassChallenge

    78High fit
  5. Invests in Biotech & life sciences · Writes Series A cheques

    Intro via Lampsy Health, backed by European Innovation Council (EIC / EIC Fund)

    74High fit
  6. gener8torTicket $100K

    Invests in Biotech & life sciences · Active in United States

    Intro via Chonex, backed by gener8tor

    74High fit
  7. Robin Hood VenturesTicket $250K–$500K

    Invests in Biotech & life sciences · Active in United States

    Intro via Vytala Health, backed by Robin Hood Ventures

    74High fit
  8. Invests in Biotech & life sciences · Invests globally

    Intro via Cromodata, backed by PharmStars Ventures

    72High fit
  9. Writes Series A cheques · Active in United States

    Intro via Neurosoft Bioelectronics, backed by Connecticut Innovations

    70High fit
  10. Seraphim SpaceTicket From $150K

    Writes Series A cheques · Invests in Deep tech & materials, adjacent to Biotech & life sciences

    Intro via G-Space, Inc, backed by Seraphim Space

    70High fit

Investment analysis

5.8C

Grade C

Rank 17 of 151

Disruption9.0/10
Business model4.0/10
Market5.0/10
Risk(lower is better)6.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Platform technology with exceptional potential, a deserving winner; the ticket should be tied to a first industrial contract.

Disruption

9/10

Microbial fermentation producing high-performance, fossil-free materials (BAYSE SAP): a change of materials platform.

Business model

4/10

Ingredient produced at commercial scale and usage tests in 2026, but no named commercial customer.

Market

5/10

TAM $10.2bn → base 5; scalability 6/10 (neutral); no international presence: no commercial customer yet → 5/10.

Risk

6/10

Lower is better

High but controlled risk: industrial scale-up and adoption by major manufacturers remain to be proven, despite $25M raised.

Strengths

  • Breakthrough bio-based platform
  • Winner of the 2026 Grand Finale

Risks

  • No named commercial customer yet
  • Costly industrial scale-up

Funding

$25M, disclosed
  1. n.d.

    pre-seed / acceleratorn/a

    IndieBio (SOSV)

  2. n.d.

    seedn/a

    GS Futures, KdT Ventures, Cavallo Ventures (existing investors before the Series A)

  3. 16 janv. 2024

    Series A$21M

    Breakout Ventures (lead), lululemon, Toyota Ventures, GS Futures, KdT Ventures, Cavallo Ventures

  4. 1 sept. 2026

    federal grant (DOE/LBNL)$4M

    US Department of Energy / Lawrence Berkeley National Lab

Amount used in the study. $21M Series A + $4M DOE/LBNL grant; aggregators at ~$34-35M as upper bound.

Note. Not consolidated: ~$34-35M according to aggregators (grants included); $21M Series A + $4M federal funding in 2026 documented

verified, nothing to correct: latest confirmed equity round = $21M Series A (Jan. 2024, Breakout Ventures, Lululemon, Toyota Ventures); $4M DOE grant in 2026. A job posting mentioned a Series B expected in early 2026, but no confirmed closing (the PitchBook profile "ZymoBiotech" is a different company with a similar name).

Team

  • Harshal Chokhawala

    Co-founder & CEO

    PhD in chemistry (UC Davis), former researcher at UC Berkeley and Lawrence Berkeley National Lab.

  • Jon Kuchenreuther

    Co-founder & Chief Scientific Officer

    Scientist from UC Berkeley, co-founder of ZymoChem (2013/2015 depending on the source).

Sources

Regional final
2026 Grand Finale champion ($1M from Pegasus)
Identification confidence
high
Founding year: 2013 (medium confidence)
Founded in 2013 by UC Berkeley postdocs according to Craft, Built In and other databases; CB Insights and VCET give 2015 craft.co
  1. 1zymochem.com/
  2. 2textileworld.com/textile-world/2024/01/zymochem-secures-21m-series-a-funding
  3. 3biofuelsdigest.com/bdigest/2024/01/30/zymochem-closes-21m-series-a-round/
  4. 4knowesg.com/finance-technology/hygiene-products-bayse-tm-replaces-fossi
  5. 5dealroom.co/news/148761-zymochem-wins-4m-doe-grant-to-reboot-us-biomanu

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet